Fremanezumab

A calcitonin gene-related peptide (CGRP) antibody injection, FDA-approved for migraine prevention in adults and episodic migraine prevention in children 6 to 17.

psilodex.org/m/fremanezumab · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: No psilocybin data
Half-life: ~31 days; Approximate, in adults. Source under Interaction below.Effect duration: Monthly or quarterly injection: drug remains for months after the last dose

Named in state rules?

Not namedColorado

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Fremanezumab”, v2026.10.05. psilodex.org/m/fremanezumab

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

FDA-approved for

Migraine prevention (adults)
Episodic migraine prevention (age 6 to 17, weight 45 kg or more)

Sources [1]

01 Interaction with psilocybin

Not studied with psilocybin; no linking mechanism is described; its label reports new or worsened high blood pressure, which psilocybin also briefly raises.

Detail Not studied with psilocybin, and no mechanism linking them has been described. Its label reports new or worsened high blood pressure after CGRP antagonists (this class of migraine drugs), and psilocybin also briefly raises blood pressure. With a half-life of about 31 days, the antibody is present at all times between doses. Separately, its label reports Raynaud's phenomenon (cold, pale fingers or toes). Sources [1]

Human data with psilocybin: No psilocybin data; based on its label
Effect duration: Monthly or quarterly injection: drug remains for months after the last dose Label half-life is about 31 days. Source
Half-life: ~31 days (FDA label, checked 2026-10-04)

Evidence types on this record

No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

1 listed · counted on reports

Raises blood pressure or heart rate: Raises blood pressure or heart rate. Psilocybin raises both for several hours, so the effects can add. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-10-04

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

AJOVY (fremanezumab-vfrm) injection · FDA label (DailyMed) — revised 2026-06 | Raises blood pressure or heart rate: 5.3 Hypertension "Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including AJOVY, in the postmarketing setting." | 12.3 Pharmacokinetics "Fremanezumab-vfrm was estimated to have a half-life of approximately 31 days."
Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18. — no reported interaction
Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976. — no reported interaction

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →